Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al.
Houssiau
F A
FA
Delannoy
A
A
Devogelaer
J P
JP
D000743:Anemia, Hemolytic / Q000139:chemically induced; D000974:Antibodies, Antinuclear / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000139:chemically induced; D017338:Cladribine / Q000009:adverse effects* / Q000276:immunology; D005260:Female; D006801:Humans; D007154:Immune System Diseases / Q000139:chemically induced*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000276:immunology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008181:Lupus Nephritis / Q000628:therapy; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged
D000974:Antibodies, Antinuclear; D007166:Immunosuppressive Agents; D017338:Cladribine